A novel delivery platform for therapeutic peptides.

Abstract

Although many peptides have therapeutic effects against diverse disease, their short half-lives in vivo hurdle their application as drug candidates. To extend the short elimination half-lives of therapeutic peptides, we developed a novel delivery platform for therapeutic peptides using an anti-hapten antibody and its corresponding hapten. We selected cotinine because it is non-toxic, has a well-studied metabolism, and is physiologically absent. We conjugated WKYMVm-NH2, an anti-sepsis therapeutic peptide, to cotinine and showed that the conjugated peptide in complex with an anti-cotinine antibody has a significantly improved in vivo half-life while retaining its therapeutic efficacy. We suggest that this novel delivery platform for therapeutic peptides will be very useful to develop effective peptide therapeutics.

• Authors: Sunyoung Park, Sang Doo Kim, Ha Young Lee, Dobeen Hwang, Joon Seong Park, Yoe-Sik Bae, Junho Chung
• Journal: Biochemical and biophysical research communications (Biochem Biophys Res Commun) Vol. 450 Issue 1 Pg. 13-8 (Jul 18 2014) ISSN: 1090-2104 [Electronic] United States
• PMID: 24857984 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Chemical References

• Oligopeptides
• Trp-Lys-Tyr-Met-Val-Met
• Cotinine

Topics

• Animals
• Cell Line
• Cotinine (administration & dosage, chemistry, pharmacokinetics)
• Drug Compounding (methods)
• Drug Delivery Systems (methods)
• Humans
• Mice
• Neutrophil Activation (drug effects)
• Neutrophils (drug effects, metabolism)
• Oligopeptides (administration & dosage, chemistry, pharmacokinetics)
• Protein Binding
• Sepsis (diagnosis, drug therapy)
• Treatment Outcome